Sandu Pharmaceuticals has informed that it enclosed Trading Approval Letter received from BSE pertaining to application made by Company in respect of the Trading of 8,50,326 equity shares of Rs 10 each to be issued at premium of Rs 10.69 bearing distinctive numbers from 8810665 to 9660990 issued to Promoter and Non-Promoters on a preferential basis pursuant to conversion of 8,50,326 warrants.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.00 |
| Dr. Reddys Labs. | 1347.95 |
| Cipla | 1442.70 |
| Zydus Lifesciences | 1100.30 |
| Lupin | 2349.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: